ArticleBritish journal of cancer2010
Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer.
Article in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023Article
- Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies.Frontiers in pharmacology · 2021Review
- Epigenetic Input Dictates the Threshold of Targeting of the Integrin-Dependent Pathway in Non-small Cell Lung Cancer.Frontiers in cell and developmental biology · 2020Article
- Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β1.The Journal of clinical investigation · 2019Article
- Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.Current treatment options in oncology · 2018Review
- Expression of Bcl-2 is a favorable prognostic biomarker in lung squamous cell carcinoma.Oncology letters · 2018Article
- Prognostic value of increased integrin-beta 1 expression in solid cancers: a meta-analysis.OncoTargets and therapy · 2018Review
- Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).Investigational new drugs · 2017Article
- miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics.Molecular cancer research : MCR · 2016Article
- Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.Cell death & disease · 2015Article
- Article
- Expression of ITGB1 predicts prognosis in colorectal cancer: a large prospective study based on tissue microarray.International journal of clinical and experimental pathology · 2015Article
- Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review.OncoTargets and therapy · 2015Article
- Lectin histochemistry reveals SNA as a prognostic carbohydrate-dependent probe for invasive ductal carcinoma of the breast: a clinicopathological and immunohistochemical auxiliary tool.International journal of clinical and experimental pathology · 2014Article
- Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.Molecular and cellular biochemistry · 2013Article
- Significance of cancer-associated fibroblasts in the regulation of gene expression in the leading cells of invasive lung cancer.Journal of cancer research and clinical oncology · 2013Article
- Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors.Cancers · 2013Article
- Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study.Diagnostic pathology · 2012Article
- Two novel determinants of etoposide resistance in small cell lung cancer.Cancer research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
introductionSurvival in small cell lung cancer (SCLC) is limited by the development of chemoresistance. Factors associated with chemoresistance in vitro have been difficult to validate in vivo. Both Bcl-2 and β(1)-integrin have been identified as in vitro chemoresistance factors in SCLC but their importance in patients remains uncertain. Tissue microarrays (TMAs) are useful to validate biomarkers but no large TMA exists for SCLC. We designed an SCLC TMA to study potential biomarkers of prognosis and then used it to clarify the role of both Bcl-2 and β(1)-integrin in SCLC.
methodsA TMA was constructed consisting of 184 cases of SCLC and stained for expression of Bcl-2 and β(1)-integrin. The slides were scored and the role of the proteins in survival was determined using Cox regression analysis. A meta-analysis of the role of Bcl-2 expression in SCLC prognosis was performed based on published results.
resultsBoth proteins were expressed at high levels in the SCLC cases. For Bcl-2 (n=140), the hazard ratio for death if the staining was weak in intensity was 0.55 (0.33-0.94, P=0.03) and for β(1)-integrin (n=151) was 0.60 (0.39-0.92, P=0.02). The meta-analysis showed an overall hazard ratio for low expression of Bcl-2 of 0.91(0.74-1.09).
conclusionsBoth Bcl-2 and β(1)-integrin are independent prognostic factors in SCLC in this cohort although further validation is required to confirm their importance. A TMA of SCLC cases is feasible but challenging and an important tool for biomarker validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.